Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chromium Picolinate in Adolescents With Acanthosis Nigricans and Insulin Resistance
NCT07371169Completed
- Sponsor
- Uruk University
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in acanthosis nigricans and insulin resistance (IR) comparing Chromium Picolinate with Placebo Control (2 arms). Primary endpoints: Change in the clinical severity of Acanthosis Nigricans at 24 weeks and Change in the severity of insulin resistance at 24 weeks. Started Jan 2025; status: completed.
02
Drugs
chromium picolinate
03
Conditions
acanthosis nigricansinsulin resistance (IR)
Beyond the preview
Go deeper on NCT07371169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07371169.